Stunning trial data accelerates the Genmab biotech pivot
- Genmab depends heavily on DARZALEX royalties, but it is building its own drug sales engine.
- EPKINLY sales reached $491 million in the first nine months of 2026, growing 47 percent year over year.
- October 2026 delivered three massive clinical wins for EPKINLY, Rina-S, and petosemtamab.
- The Merus deal added petosemtamab and BIZENGRI, but it also brought substantial acquisition debt.
- The main test is whether new owned products can offset a DARZALEX royalty decline starting in 2029.
A cash-rich pivot with massive clinical wins
Genmab is changing its story. For years, much of the money came from royalties on partner sales of drugs like DARZALEX. Now the company wants to become a full biotech, meaning it develops drugs, runs trials, and sells more products itself.
The bull case is that the old royalty stream gives Genmab time and cash to build the new model, and that model is succeeding. Commercial execution is strong. EPKINLY reached $491 million in sales in the first nine months of 2026, up 47 percent from a year earlier.
October 2026 removed massive clinical risk. Genmab delivered highly successful late-stage trial results across three key assets. EPKINLY cut the risk of disease progression or death by 51 percent in frontline lymphoma. Rina-S showed a 71 percent reduction in progression risk for ovarian cancer. Petosemtamab cut the risk of death by half in head and neck cancer.
The bear case is concentration and timing. DARZALEX royalties are still the main profit base, and Genmab says U.S. daratumumab patents expire in 2029, when royalties should begin to fall materially. The stock needs the new late-stage data to turn into rapid approvals and sales before that royalty cliff matters.
Royalties pay for owned launches
Genmab makes money in several ways. The biggest is royalties, which are payments based on sales of drugs that partners sell. In 2025, royalties were $3.102 billion out of $3.720 billion of total revenue, or about 83 percent of revenue.
The faster-growing part is direct and partnered product sales. Genmab records EPKINLY net product sales in the U.S. and Japan under its AbbVie partnership. It also records or shares economics from Tivdak, depending on the country. In the first nine months of 2026, EPKINLY reached $491 million in sales, while Tivdak reached $131 million.
The Merus acquisition pushes Genmab further toward owning more of its future. It added petosemtamab, BIZENGRI royalties, and antibody technology platforms. The tradeoff is financial. Genmab took on heavy debt for the deal, with $4.1 billion effectively fixed at about a 6.6 percent interest rate, and management wants gross leverage below 3x by the end of 2027.
The drugs that matter
DARZALEX royalties
DARZALEX is sold by J&J, while Genmab receives royalties. It is the main cash source today, but U.S. patent rights on daratumumab expire in 2029.
EPKINLY
EPKINLY is a bispecific antibody. Sales reached $491 million in the first nine months of 2026, and spectacular frontline lymphoma trial data expands its future market.
Tivdak
Tivdak is an antibody drug conjugate. First nine months of 2026 sales reached $131 million, and Genmab is taking more responsibility outside the U.S. and China.
Rina-S
Rina-S is a late-stage antibody drug conjugate aimed at ovarian and endometrial cancers. It delivered highly compelling progression-free survival data in October 2026.
Petosemtamab
Petosemtamab came with the Merus deal. It showed a major overall survival benefit in frontline head and neck cancer and is expanding into colorectal cancer trials.
BIZENGRI
BIZENGRI was added through Merus and gives Genmab another royalty medicine, though management does not expect the revenue to be material.
Revenue still starts with royalties
The mix uses 2025 revenue by type from Genmab's Annual Report Note 2.1. Royalties are the clear majority, so the company is still exposed to partner sales and patent timing even as owned product sales grow.
What could break the thesis
DARZALEX royalty cliff
High impact · High oddsDARZALEX royalties are the main profit base. Genmab says U.S. daratumumab patent rights expire in 2029 and royalties should begin to decline materially after that. If the new pipeline drugs do not scale fast enough, earnings power could fall.
Regulatory delays for new data
High impact · Medium oddsGenmab generated fantastic trial data in late 2026 for EPKINLY, Rina-S, and petosemtamab. The risk now shifts to regulatory execution. Any delay from the FDA or limited label wording would slow the commercial launch for these major growth drivers.
Petosemtamab competitive pressure
Medium impact · Medium oddsIn head and neck cancer, petosemtamab faces intense competitive pressure from Johnson and Johnson's amivantamab. Genmab claims a massive safety advantage, but if doctors do not see the differentiation, the drug could lose market share.
Debt and integration load
Medium impact · Medium oddsThe Merus deal added $5.5 billion of debt and integration work. Genmab says $4.1 billion is effectively fixed at about a 6.6 percent interest rate and targets gross leverage below 3x by the end of 2027. If trial costs rise, that deleveraging plan becomes harder.
In one breath
What does Genmab actually do?
Genmab develops antibody drugs, mostly for cancer. It also earns royalties when partners sell medicines that use Genmab science, with DARZALEX being the biggest example.
Why is DARZALEX so important to Genmab?
DARZALEX royalties are the largest part of revenue and help fund Genmab's pipeline. The risk is that U.S. patent rights on daratumumab expire in 2029, when those royalties are expected to decline materially.
What is the main bull case for GMAB stock?
The bull case is that Genmab is successfully using royalty cash to build a stronger owned drug business. Late 2026 data for EPKINLY, Rina-S, and petosemtamab was highly positive, which could widen the future revenue base.
What should investors watch in 2027?
The biggest items are FDA approvals for Rina-S, petosemtamab, and EPKINLY based on their recent clinical trial wins. Investors should also watch whether Genmab keeps lowering its debt leverage after the Merus acquisition.
Sources and research notes
This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.
- Thesis reviewed
- November 8, 2026
- Score data
- November 15, 2026
- Reviewed by
- Shivam Bharuka
Comparable Biotechnology companies
Companies near Genmab A/S in Finn's Biotechnology industry ranking.

